Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBenjamin Heyman

Discussion

Loading...

Member takes

Overview

Phase II trial shows improved efficacy and safety profile of triplet therapy in untreated follicular lymphoma patients, suggesting potential as frontline treatment.

Key Points

  • To evaluate the safety and efficacy of triplet therapy with obinutuzumab, ibrutinib, and venetoclax in patients with untreated follicular lymphoma.
  • Single arm, phase II, open label trial across 4 NCI-designated Comprehensive Cancer Centers.
  • Participants aged 18 and older received triplet therapy for 24 cycles or until disease progression.
  • Primary objective was complete response rate at 12 months as per Lugano criteria.
  • Overall response rate for the cohort was 92.5%, with a 76% complete response rate at 12 months.
  • Two-year progression-free survival and overall survival rates were 82% and 97%, respectively.
  • 80% of patients achieved minimal residual disease negativity at last evaluation.

Cite This Study

Benjamin Heyman (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dffchttps://doi.org/10.1182/blood-2025-5378
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  2. 2Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study2026
  3. 3Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  4. 4Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study2024
  5. 5Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025